Baxter International Inc.

Baxter Healthcare Sa

National University of Singapore

St. Jude Children's Research Hospital

Unum Therapeutics Inc.

Sotio Biotech Inc.

Baxalta Gmbh

Kathleen McGinness

John Louis Diener

Jeffrey C Kurz

Robert Schaub

Jennifer Nelson

Ryan Genga

Emily Waters

Charles Wilson

Dario Campana

Gregory Motz

Ko Kudo

Robert G Schaub

Luke Barron

Michael Fray

Seth Ettenberg

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof

Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8&#x3b1;); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3&#x3b6;). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.

Chimeric receptors and uses thereof in immune therapy

The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics

Growing community of inventors

Cambridge, MA, United States of America

Kathleen McGinness